Life Healthcare HEPS from cont. ops +59% to 139c beating the BB consensus of 114c | Revenue +12.7% to R25.5bn, driven by growth in southern Africa and NeuraCeq sales (an imaging agent used in PET scans) | Paid patient days in acute hospitals +1.6% | Disposals enabled a special divi of 600c in April & Net debt to EBITDA reduced to 0.45x from 2.0x in FY23 | Final div +14.8% to 31 cents, with an additional special dividend of 70 cents.
Click here to read the SENS